10
Participants
Start Date
June 30, 2006
Primary Completion Date
April 30, 2009
Study Completion Date
April 30, 2009
Suberoylanilide hydroxamic acid
400 mg QD (every day) for five days, followed by 9 days of no vorinostat
USC/Norris Comprehensive Cancer Center, Los Angeles
Merck Sharp & Dohme LLC
INDUSTRY
University of Southern California
OTHER